Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

8.29
-0.7000-7.79%
Post-market: 8.28-0.0100-0.12%19:57 EDT
Volume:27.81M
Turnover:238.14M
Market Cap:3.76B
PE:-11.75
High:9.30
Open:9.08
Low:8.15
Close:8.99
52wk High:9.36
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.25
T/O Rate:7.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:5.10
PE(LYR):-7.58

Loading ...

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 18

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 18

Does Reaffirmed 2026 Revenue Guidance And Cash Runway To 2028 Change The Bull Case For Iovance (IOVA)?

Simply Wall St.
·
Jul 05

Iovance Publishes Corporate Presentation on TIL Cell Therapy Platform, Amtagvi Launch and Pipeline Updates

Reuters
·
Jul 01

3 US Growth Stocks Analysts See Delivering Strong Earnings Through 2029

Simply Wall St.
·
Jun 25

Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings

Simply Wall St.
·
Jun 23

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Jun 22

Iovance grants inducement stock options for 140,860 shares at $3.91 each

Reuters
·
Jun 20

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 20

BRIEF-Iovance Biotherapeutics Inc Files For Mixed Shelf

Reuters
·
Jun 19

Iovance Biotherapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 19

Iovance Biotherapeutics Inc: Sale Agreement Prospectus Supplement Covering Offering of up to $89.7 Mln Common Stock

THOMSON REUTERS
·
Jun 19

Iovance Biotherapeutics Inc Files for Mixed Shelf - SEC Filing

THOMSON REUTERS
·
Jun 19

Iovance Biotherapeutics (IOVA) Stock Valuation After Australia’s Conditional Approval Of Amtagvi

Simply Wall St.
·
Jun 15

Iovance says Australia regulator approves Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 11

Iovance’s Australian Amtagvi Nod Adds Test For Valuation Upside

Simply Wall St.
·
Jun 05

BRIEF-Iovance's Amtagvi Granted Approval For Treatment Of Advanced Melanoma In Australia

Reuters
·
Jun 04

Iovance receives Australian approval of Amtagvi for advanced melanoma

TIPRANKS
·
Jun 04

Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 04

Iovance’s Amtagvi® (Lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

THOMSON REUTERS
·
Jun 04